• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

无抗凝治疗的机械瓣膜置换术：一例报告

Mechanical valve replacement without anticoagulation: a case report.

作者信息

Wang Yapeng, Lin Min, Ge Shenglin, Feng Junbo

机构信息

Department of Cardiovascular Surgery, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei 230022, Anhui, People's Republic of China.

出版信息

Eur Heart J Case Rep. 2021 Jan 15;5(1):ytaa566. doi: 10.1093/ehjcr/ytaa566. eCollection 2021 Jan.

DOI:10.1093/ehjcr/ytaa566
PMID:33644653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7898660/
Abstract

BACKGROUND

For patients who undergo mechanical valve replacement, the greatest disadvantage is that they require long-term or permanent use of anticoagulant therapy to prevent thromboembolism. To date, mechanical valve replacement without anticoagulation has been published in the literature.

CASE SUMMARY

We present the case of a 75-year-old female who underwent mechanical mitral valve replacement (MVR) on midJune, 2007. However, this patient had not been taking anticoagulant medication since she experienced warfarin overdose in the first month after the operation. She had been well without using any anticoagulation, and there were no complications of the mechanical valve.

DISCUSSION

There was no thrombosis for such a long period of time because she suffered from FX deficiency. To the best of our knowledge, she may be the only patient who has been well without any anticoagulation since not taking warfarin 12 years ago.

摘要

背景

对于接受机械瓣膜置换术的患者而言，最大的不利之处在于他们需要长期或终身使用抗凝治疗以预防血栓栓塞。迄今为止，文献中已报道了无需抗凝的机械瓣膜置换术案例。

病例摘要

我们呈现一名75岁女性的病例，该患者于2007年6月中旬接受了二尖瓣机械瓣膜置换术（MVR）。然而，该患者自术后第一个月华法林过量以来就未服用抗凝药物。她未使用任何抗凝药物却状况良好，且机械瓣膜未出现任何并发症。

讨论

由于她患有因子X缺乏症，所以在如此长的时间内未发生血栓形成。据我们所知，自12年前停用华法林以来，她可能是唯一未进行任何抗凝治疗却状况良好的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/ec3e8170aef7/ytaa566f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/9ae5b13a074d/ytaa566f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/6793f5d3b42a/ytaa566f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/c7ac0265e224/ytaa566f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/ec3e8170aef7/ytaa566f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/9ae5b13a074d/ytaa566f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/6793f5d3b42a/ytaa566f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/c7ac0265e224/ytaa566f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ca/7898660/ec3e8170aef7/ytaa566f4.jpg

相似文献

1
Mechanical valve replacement without anticoagulation: a case report.无抗凝治疗的机械瓣膜置换术：一例报告
Eur Heart J Case Rep. 2021 Jan 15;5(1):ytaa566. doi: 10.1093/ehjcr/ytaa566. eCollection 2021 Jan.
2
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.生物人工心脏瓣膜置换术后早期血栓栓塞风险高。
J Am Coll Cardiol. 1995 Apr;25(5):1111-9. doi: 10.1016/0735-1097(94)00563-6.
3
Anticoagulant management of pregnant women with mechanical heart valve replacement during perioperative period.围手术期机械心脏瓣膜置换术后孕妇的抗凝管理
Arch Gynecol Obstet. 2016 Jan;293(1):69-74. doi: 10.1007/s00404-015-3768-0. Epub 2015 Jun 6.
4
Apixaban use in an atrial fibrillation patient with double mechanical heart valves: a case report.阿哌沙班在一名患有双机械心脏瓣膜的心房颤动患者中的应用：一例病例报告。
Eur Heart J Case Rep. 2021 Jul 31;5(7):ytab285. doi: 10.1093/ehjcr/ytab285. eCollection 2021 Jul.
5
Thrombo-embolic and bleeding complications in patients with mechanical valve replacements--a prospective observational study.机械瓣膜置换患者的血栓栓塞和出血并发症——一项前瞻性观察研究。
S Afr Med J. 2006 Aug;96(8):710-3.
6
Diffused calcification in a patient with long-term warfarin therapy: a case report.长期接受华法林治疗患者的弥漫性钙化：一例报告
Eur Heart J Case Rep. 2022 Sep 1;6(9):ytac364. doi: 10.1093/ehjcr/ytac364. eCollection 2022 Sep.
7
Clinical observation of postoperative warfarin anticoagulation in 300 patients undergoing mitral valve replacement with a carbomedics mechanical valve.300例接受卡波美克斯机械瓣膜二尖瓣置换术患者术后华法林抗凝治疗的临床观察
Heart Surg Forum. 2015 Apr 28;18(2):E063-6. doi: 10.1532/hsf.1241.
8
Early postoperative anticoagulation after mechanical valve replacement: a Canadian survey.机械瓣膜置换术后早期抗凝治疗：一项加拿大调查。
J Heart Valve Dis. 2006 Jul;15(4):581-7.
9
Pregnancy after mechanical mitral valve replacement.机械二尖瓣置换术后妊娠
J Heart Valve Dis. 2003 May;12(3):370-6.
10
An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/repair.英国心胸外科顾问医师瓣膜置换/修复术后抗凝治疗实践的审计
J Heart Valve Dis. 2005 Sep;14(5):576-82.

引用本文的文献

1
Challenges Faced and Lessons Learned: The Journey of a 22-Year-Old Male with a Mechanical Heart Valve Complicated by Ischemic Stroke in a Developing Country: A Sub-Saharan Africa Prospect.面临的挑战与经验教训：一名22岁患有机械心脏瓣膜并并发缺血性中风的男性在发展中国家的经历：撒哈拉以南非洲的前景
Int Med Case Rep J. 2024 May 16;17:465-470. doi: 10.2147/IMCRJ.S456041. eCollection 2024.
2
Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis.依度沙班与华法林治疗心房颤动对肾功能的疗效和安全性：一项系统评价和荟萃分析
Medicines (Basel). 2023 Jan 16;10(1):13. doi: 10.3390/medicines10010013.

本文引用的文献

1
International normalized ratio for the guidance of warfarin treatment in elderly patients after cardiac valve replacement.国际标准化比值用于指导老年心脏瓣膜置换术后患者的华法林治疗。
Exp Ther Med. 2019 Feb;17(2):1486-1491. doi: 10.3892/etm.2018.7078. Epub 2018 Dec 10.
2
Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study.利伐沙班与华法林在机械心脏瓣膜患者中的比较：RIWA 研究的原理和设计。
Drugs R D. 2018 Dec;18(4):303-308. doi: 10.1007/s40268-018-0249-5.
3
Anticoagulation in atrial fibrillation with factor X deficiency-A management dilemma.
伴有因子X缺乏的心房颤动的抗凝治疗——一个管理难题。
Clin Case Rep. 2018 Jul 22;6(9):1781-1785. doi: 10.1002/ccr3.1731. eCollection 2018 Sep.
4
Mechanical Valve Thrombosis on Rivaroxaban: Are Novel Anticoagulants Really an Option?利伐沙班治疗期间发生机械瓣膜血栓形成：新型抗凝剂真的是一种选择吗？
Methodist Debakey Cardiovasc J. 2017 Apr-Jun;13(2):73-75. doi: 10.14797/mdcj-13-2-73.
5
Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania.大洋洲常见免疫球蛋白重链等位基因与风湿性心脏病风险的关联。
Nat Commun. 2017 May 11;8:14946. doi: 10.1038/ncomms14946.
6
Factor X and its deficiency states.
Haemophilia. 1997 Jul;3(3):159-72. doi: 10.1046/j.1365-2516.1997.00106.x.
7
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.依达赛珠单抗用于逆转 Xa 因子抑制剂的活性。
N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11.
8
Inherited Factor X (Stuart-Prower Factor) deficiency and its management.遗传性因子X（斯图尔特-普劳尔因子）缺乏症及其管理。
Med J Armed Forces India. 2015 Jul;71(Suppl 1):S184-6. doi: 10.1016/j.mjafi.2014.01.007. Epub 2014 Apr 3.
9
Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study).风湿性心脏病循证干预措施的特征、并发症及证据空白：全球风湿性心脏病注册研究（REMEDY研究）
Eur Heart J. 2015 May 7;36(18):1115-22a. doi: 10.1093/eurheartj/ehu449. Epub 2014 Nov 25.
10
Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: protocol.生物人工瓣膜置换术后达比加群与华法林用于房颤术后管理的比较：方案
JMIR Res Protoc. 2014 Apr 1;3(2):e21. doi: 10.2196/resprot.3014.